RECRUITING

Open Label, Controlled, Post Marketing, Registry Study of Ribociclib (Ribo) Treatment Adherence and Patient Reported Outcomes in Participants Using ReX Technology Platform

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Primary Objective: • To assess the persistence of ReX technology platform use, measured by the percentage (%) of participants who used ReX: 1) throughout the study period and 2) before the treatment discontinuation. Secondary Objective: • To evaluate the impact of the ReX technology platform on ribo treatment duration and ribo dose taking adherence as compared to control group.

Official Title

Study of Ribociclib (Ribo) Treatment Adherence Clinical Study Protocol

Quick Facts

Study Start:2024-03-30
Study Completion:2026-01-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06344416

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. Age 18 years or older
  2. Willing and able to provide informed consent
  3. Able to understand and follow study procedures
  4. Stable medical condition
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Study Contact

Natan Natan Paz
CONTACT
+972 52 6577126
natan.p@dosentrx.com

Study Locations (Sites)

CARTI
Little Rock, Arkansas, 72205
United States
Allina
Minneapolis, Minnesota, 55407
United States
Texas Oncology
Austin, Texas, 78705
United States
Virginia Cancer Center
Richmond, Virginia, 23229
United States
Lumicera
Madison, Wisconsin, 53717
United States

Collaborators and Investigators

Sponsor: Dosentrx Ltd.

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-03-30
Study Completion Date2026-01-30

Study Record Updates

Study Start Date2024-03-30
Study Completion Date2026-01-30

Terms related to this study

Keywords Provided by Researchers

  • Solid oral medication

Additional Relevant MeSH Terms

  • Any Solid Oral Medication